Bright Minds Biosciences Statistics Share Statistics Bright Minds Biosciences has n/a
shares outstanding. The number of shares has increased by 58.68%
in one year.
Shares Outstanding n/a Shares Change (YoY) 58.68% Shares Change (QoQ) 0.56% Owned by Institutions (%) 99.99% Shares Floating 4.93M Failed to Deliver (FTD) Shares 2,776 FTD / Avg. Volume 4.87%
Short Selling Information The latest short interest is 201.53K, so 2.84% of the outstanding
shares have been sold short.
Short Interest 201.53K Short % of Shares Out 2.84% Short % of Float 4.17% Short Ratio (days to cover) 3.27
Valuation Ratios The PE ratio is -2.43 and the forward
PE ratio is -8.03.
Bright Minds Biosciences's PEG ratio is
0.04.
PE Ratio -2.43 Forward PE -8.03 PS Ratio 0 Forward PS n/a PB Ratio 1.23 P/FCF Ratio -3.69 PEG Ratio 0.04
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Bright Minds Biosciences.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 11.32,
with a Debt / Equity ratio of 0.02.
Current Ratio 11.32 Quick Ratio 11.32 Debt / Equity 0.02 Debt / EBITDA n/a Debt / FCF -0.06 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee n/a Employee Count undefined Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 3300.81% in the
last 52 weeks. The beta is -0.14, so Bright Minds Biosciences's
price volatility has been lower than the market average.
Beta -0.14 52-Week Price Change 3300.81% 50-Day Moving Average 35.05 200-Day Moving Average 34.55 Relative Strength Index (RSI) 55.33 Average Volume (20 Days) 56,995
Income Statement
Revenue n/a Gross Profit n/a Operating Income -2.62M Net Income -2.8M EBITDA n/a EBIT -2.62M Earnings Per Share (EPS) -0.65
Full Income Statement Balance Sheet The company has 5.72M in cash and 118.96K in
debt, giving a net cash position of 5.6M.
Cash & Cash Equivalents 5.72M Total Debt 118.96K Net Cash 5.6M Retained Earnings -34.35M Total Assets 52.5M Working Capital 51.76M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -1.85M
and capital expenditures 0, giving a free cash flow of -1.85M.
Operating Cash Flow -1.85M Capital Expenditures n/a Free Cash Flow -1.85M FCF Per Share -0.43
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields DRUG does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for DRUG is $80,
which is 89.7% higher than the current price. The consensus rating is "Buy".
Price Target $80 Price Target Difference 89.7% Analyst Consensus Buy Analyst Count 7
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jul 14, 2023. It was a
backward
split with a ratio of 1:5.
Last Split Date Jul 14, 2023 Split Type backward Split Ratio 1:5
Scores Altman Z-Score 268.34 Piotroski F-Score 2
